Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, bolstering its portfolio on ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an ...

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown its team year-over-year. At a time when many life sciences companies are ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

Rouse had presented with symptoms including intense swelling in her legs that she originally thought could be linked to her ...

Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...

Explore Vertex Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for VRTX. Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 ...

The Zacks Consensus Estimate for Vertex’s fourth-quarter 2024 earnings is pegged at 14 cents per share, implying a year-over-year increase of 7.7%. Vertex’s earnings surpassed the Zacks ...